Garrison Michael David sold $160K of BDX
Garrison Michael David (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares of BECTON DICKINSON & CO (BDX) at $145.66 ($0.16M total) on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale is unlikely to change near-term fundamentals, but it can marginally influence short-term sentiment among traders monitoring insider activity.
Market read
Traders may note the sale as a sentiment datapoint, but the 10b5-1 structure limits actionable inference.
What to watch
Insider sales can be tax- or diversification-driven; without additional context (e.g., repeated sales, purchases, or changes in guidance), the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Becton Dickinson & Co.
Ticker impact
Becton Dickinson insider Garrison Michael David sold 1,100 shares at $145.66 under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a Form 4 open-market sale with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal read-through for medical devices; this is a single-insider transaction without operational or regulatory implications.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerBecton Dickinson & Co
Company whose insider transaction was disclosed via SEC Form 4.
- insiderGarrison Michael David
EVP & Pres, Med. Essential & BioPharm; reported an open-market sale under a 10b5-1 plan.
%252FBD%252520Canada's%252520head%252520office%252520building%252520in%252520Mississauga%25252C%252520On%25252C%252520Canada_%252520%252520By%252520JHVEPhoto.jpeg&w=2048&q=75)
